Onco-ctTrace is GenomeScan’s advanced liquid biopsy service, powered by the HederaDx HP2 panel (RUO) — a 32-gene ctDNA test designed to detect cancer-related mutations from a simple blood sample. It enables clinicians to understand, monitor, and personalize cancer treatment with unmatched precision.
Solid Tumors
Plasma sample
Unlock the power of precision oncology with a comprehensive, actionable molecular profile—covering SNVs, CNVs, fusions, and MSI—to guide personalized treatment decisions across the most common solid tumors.
Onco-ctTrace supports your team across the entire cancer care continuum with the molecular insights needed to make confident, timely decisions. Built for the unique demands of pharmaceutical and biotech innovators, our platform empowers you to:
Whether you’re developing targeted therapies, refining clinical trial endpoints, or advancing companion diagnostics, Onco-ctTrace delivers the actionable data that drives precision oncology forward. For research use only. Not for use in diagnostic procedures.
Accelerate every stage of your liquid biopsy pipeline with GenomeScan’s Onco-ctTrace platform. Our ISO 17025-accredited solution is purpose-built for the demanding needs of pharmaceutical R&D, offering a streamlined, end-to-end workflow—from biomarker discovery to clinical trial stratification. Unlock high-resolution genomic insights that power precision oncology and drive smarter, faster decision-making.
Match patients to therapies based on actionable ctDNA mutations.
Onco-ctTrace helps you find the right patients faster by identifying key ctDNA mutations like EGFR and ALK in NSCLC. With precise matching to targeted therapies, you can boost trial success, improve response rates, and reduce variability—accelerating your path to approval.
Track ctDNA to assess treatment response and detect resistance early.
Onco-ctTrace gives you real-time insight into treatment response by tracking ctDNA levels. A drop in VAF suggests therapy is working, while rising levels may signal resistance mutations like ESR1. These early indicators help you act faster—refining protocols, adjusting treatments, and improving patient outcomes.
Detect minimal residual disease to predict early relapse.
Onco-ctTrace helps you stay ahead of recurrence by detecting minimal residual disease (MRD) through ultra-sensitive ctDNA analysis. Early signs—like re-emerging KRAS mutations post-surgery—can reveal relapse before symptoms appear, giving you time to act. Strengthen endpoints and tailor follow-up with confidence.
Validate biomarkers and support companion diagnostic tools.
Onco-ctTrace helps you validate predictive biomarkers like MSI and PIK3CA using high-resolution ctDNA data. This supports companion diagnostic development and aligns with ESCAT tier I–II targets—ensuring your therapies reach the right patients. Stronger trials, clearer regulatory paths, smarter precision oncology.
Correlate ctDNA with outcomes for translational insights.
Onco-ctTrace links ctDNA trends to real clinical outcomes, offering deeper insight into treatment effectiveness. Persistent ctDNA despite radiographic response may signal early relapse risk—before it appears on scans. Use these insights to refine biomarkers, design smarter trials, and translate molecular shifts into therapeutic impact.
We have summarized key information about our Onco-ctTrace service into a service specification sheet.
Fill out the form below or reach out directly to our Head of Oncology, Stefanie, at oncology@genomescan.nl— we’ll get back to you shortly to discuss how we can support your project.
